Organon Sets July Vote on $14‑per‑Share Sun Pharma Takeover
New activity is brewing for Organon ( (OGN) ). The company has submitted a Form DEFM14A to the SEC, indicating an upcoming shareholder vote. This form gives shareholders all the information they need to develop an informed vote. Read on to learn more about the proposed company action.
Claim 55% Off TipRanks
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Organon has entered into a definitive merger agreement under which Sun Pharmaceutical Holdings USA, Inc. will acquire the company by merging its subsidiary Sun Pharma America, Inc. into Organon, valuing each Organon share at $14.00 in cash. The board of directors has unanimously deemed the deal fair and in the best interests of stockholders, and is urging investors to vote in favor of the merger and a related advisory vote on executive compensation at a virtual special meeting on July 23, 2026.
Completion of the transaction hinges on approval by a majority of outstanding common shares, with non‑voting or abstaining shares effectively counted against the deal. Stockholders who oppose the transaction and follow Delaware law procedures will have appraisal rights, while the all‑cash offer, if approved, will take Organon private under Sun Pharma’s control and deliver an immediate cash exit to existing equity holders.
The most recent analyst rating on (OGN) stock is a Hold
with a $14.00 price target.
To see the full list of analyst forecasts on Organon stock,
see the OGN Stock Forecast page.
Spark’s Take on OGN Stock
According to Spark, TipRanks’ AI Analyst, OGN is a Neutral.
The score is primarily weighed down by weakened financial performance—sharp TTM revenue decline, lower net profitability, and high leverage—despite strong cash generation. Technicals are constructive with an uptrend, and valuation is supported by a moderate P/E and very high dividend yield. A major positive offset is the announced all-cash acquisition, which provides a clear premium path but carries deal-completion risk.
To see Spark’s full report on OGN stock,
click here.
More about Organon
Organon & Co. is a pharmaceutical company focused on women’s health and other specialty medicines, operating as a publicly traded U.S. corporation. Its common stock is listed for public investors, and the company is now positioned to become a wholly owned subsidiary of Sun Pharmaceutical Holdings USA, Inc. if the proposed merger is approved.
Average Trading Volume: 8,578,294
Technical Sentiment Signal: Hold
Current Market Cap: $3.53B
For a thorough assessment of OGN stock, go to TipRanks’ Stock Analysis page.
